Advances in drug discovery, coupled with regulatory approvals for novel drugs like inotuzumab for acute lymphoblastic leukemia, underscore the industry’s commitment to addressing unmet clinical needs.

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

Life was good for Betsy Ehrenberg. It was 2017, and she was 68, a partner at Boston law firm Pyle Rome Ehrenberg PC. She represented unions in collective bargaining matters and workers who’d ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today. Salim Syed’s rating ...

HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update. Hemogenyx Pharmaceuticals has secured a £600,000 investment from an institutional ...

As word of his diagnosis spread, friends, neighbors, and even strangers wanted to help. A small committee of friends and ...

Autolus Therapuetics plc has been granted FDA approval for Aucatzyl (obecabtagene autoleucel) for the treatment of acute lymphoblastic leukemia in adults, becoming the first marketed CAR T therapy ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

In 2020, leukemia (cancer of the blood) accounted for approximately 2.5 per cent of all new cancer cases and 3.1 per cent of deaths globally. Of these, chronic myeloid leukemia (CML) is a subtype that ...